Supplementary MaterialsSupplementary Information 41467_2018_8193_MOESM1_ESM. capacity to inhibit glucagon secretion is usually lost following genetic ablation of insulin receptors in the somatostatin-secreting -cells, when insulin-induced somatostatin secretion is usually suppressed by dapagliflozin (an inhibitor of sodium-glucose co-tranporter-2; SGLT2) or when the action of secreted somatostatin is usually prevented by somatostatin receptor (SSTR) antagonists. Administration of the… Continue reading Supplementary MaterialsSupplementary Information 41467_2018_8193_MOESM1_ESM. capacity to inhibit glucagon secretion is usually